

## Program

Self-paced learning package: Available from Friday 2 September 2022

Topic and presenters	Learning objectives
<p><b>Foundational principles – pathophysiology, diagnostics and cellular therapies</b></p> <p><b>John Coutsouvelis</b>, Senior Clinical Pharmacist, Alfred Health, Melbourne, Vic</p> <p><b>Dr Tamasine Stewart</b>, Haematology Laboratory Registrar, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</p> <p><b>Dr Ray Mun Koo</b>, Bone Marrow Transplant Fellow, Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</p> <p><b>Dr Mark Dowling</b>, Cellular Therapies Fellow, Victorian Cancer Agency Mid-Career Fellow, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</p>	<ul style="list-style-type: none"> <li>• Describe the different methodologies used in diagnosing haematological malignancies</li> <li>• Explain the principles of fluorescence <i>in situ</i> hybridisation (FISH) and next generation sequencing</li> <li>• Explain the diagnostic tests required for establishing the diagnosis of acute leukaemia</li> <li>• Describe the basic principles of haematopoietic stem cell transplant and CAR T cell therapy</li> <li>• Explain the indications of haematopoietic stem cell transplant and CAR T cell therapy</li> <li>• Explain the basic principles of conditioning therapy for haematopoietic stem cell transplant and CAR T cell therapy</li> <li>• Identify the most common toxicities of haematopoietic stem cell transplant and CAR T cell therapy, including graft versus host disease</li> </ul>
<p><b>Acute myeloid leukaemia/Myelodysplastic syndrome</b></p> <p><b>Dr Andrew Wei</b>, Stream Leader- Acute Leukaemia and MDS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</p> <p><b>Dr Christopher Leow</b>, Haematologist, Monash Health, Western Health, Melbourne, Vic</p>	<ul style="list-style-type: none"> <li>• Describe of the pathophysiology of acute myeloid leukaemia (AML)</li> <li>• Assess the prognostic impact of relevant cytogenetics or molecular mutations of acute myeloid leukaemia</li> <li>• Explain treatment paradigm for acute myeloid leukaemia (AML) in young and fit patients</li> <li>• Describe the most commonly used treatment regimens for AML and their place in therapy</li> <li>• Explain the therapeutic relevance of common genetic mutation drug targets (FLT3, IDH2)</li> <li>• Identify limitations of AML treatment in older/unfit patients</li> <li>• Describe treatment options for patients unfit for standard induction</li> <li>• Describe the most commonly used regimens for AML and understand their place in therapy</li> <li>• Explain of the pathophysiology of myelodysplastic syndrome (MDS)</li> <li>• Outline the risk factors, prognosis and risk of progression to acute leukaemia.</li> <li>• Describe treatment options for myelodysplastic syndrome</li> </ul>

# EXTENSION SEMINAR IN HAEMATOLOGY

<p><b>Acute Lymphoblastic Leukaemia</b></p> <p><b>Dr David Yeung</b>, Head of Unit, Haematology and BMT, Central Adelaide Local Health Network; Clinical Associate Professor, Adelaide Medical School; SA Cancer Council Beat Cancer Clinical Investigator; Post Doc, South Australian Health and Medical Research Institute, Adelaide, SA</p> <p><b>Dr Shaun Fleming</b>, Clinical &amp; Laboratory Haematologist, Alfred Health, Melbourne, Vic</p>	<ul style="list-style-type: none"> <li>• Explain the basic clinical presentation of acute lymphoblastic leukaemia</li> <li>• Explain the principles of disease risk stratification through complete diagnostic workshop in ALL, and how this affects treatment decisions</li> <li>• Explain the treatment paradigm for acute lymphoblastic leukaemia in patients who are older or not appropriate for adolescent and young adults (AYA) protocols.</li> <li>• Describe the most commonly used regimens for ALL and understand their place in therapy</li> <li>• Recognise limitations of treatment in older/unfit patients</li> <li>• Explain the treatment paradigm for acute lymphoblastic leukaemia (ALL) in young and fit adult patients</li> <li>• Outline the role of stem cell transplant and CAR T cell therapy in the treatment of ALL</li> <li>• Detail common complications from intense treatment regimens for acute lymphoblastic leukaemias</li> </ul>
<p><b>Supportive care and toxicities</b></p> <p><b>Associate Professor Kate Stern</b>, A/Prof of Obstetrics and Gynaecology, Head of Reproductive Services and Head of Endocrine and Metabolic Service, Royal Women's Hospital, Melbourne, Vic</p> <p><b>Philip Selby</b>, Senior Clinical Pharmacist, Haematology, Royal Adelaide Hospital; PHD Candidate, University of Adelaide, School of Medicine</p> <p><b>Shevon Fernando</b>, Senior Haematology Pharmacist, Alfred Health, Vic</p>	<ul style="list-style-type: none"> <li>• Describe factors affecting the extent of chemotherapy or radiotherapy induced gonadotoxicity</li> <li>• Describe fertility preservation options or strategies for cancer patients undergoing chemotherapy and/or radiotherapy</li> <li>• Identify supportive care requirements in patients undergoing treatment for acute leukaemia</li> <li>• Explain how to manage potential drug interactions, problematic toxicities and practical issues with supportive care medications in acute leukaemia</li> <li>• Briefly describe differing supportive care requirements with different acute leukaemia treatment regimens</li> <li>• Explain the reasons supportive care is needed in bone marrow transplant.</li> <li>• Describe the role of antimicrobial prophylaxis in bone marrow transplant and the therapeutic agents utilised.</li> <li>• Outline preventative strategies for mucositis, neutropenia, nausea and vomiting in bone marrow transplant.</li> <li>• Discuss the principals of graft versus host disease and the therapeutic agents utilised for its prevention.</li> </ul>
<p><b>Relapsed/refractory Diffuse Large B-Cell Lymphoma</b></p> <p><b>Dr Nick Murphy</b>, Consultant Haematologist, Royal Hobart Hospital, Tas</p>	<ul style="list-style-type: none"> <li>• Briefly outline the pathophysiology of relapsed/refractory diffuse large B cell lymphoma (DLBCL)</li> <li>• Describe poor prognostic factors for DLBCL</li> <li>• Overview the prognosis of relapsed / refractory disease</li> <li>• Outline treatment making decisions for refractory/relapsed (RR) diffuse large B cell lymphoma (DLBCL)</li> <li>• Describe treatment options in the RR setting</li> <li>• Explain the role of stem cell transplant and CAR T trials in the treatment of RR DLBCL</li> </ul>
<p><b>Relapsed/refractory Multiple Myeloma</b></p> <p><b>Dr Michael Low</b>, Consultant Haematologist, Myeloma Lead &amp; Head of Haematology training, Monash Health; Director of Physician Education Casey Hospital, Melbourne, Vic</p>	<ul style="list-style-type: none"> <li>• Briefly outline the pathophysiology of relapsed/refractory multiple myeloma (MM)</li> <li>• Describe poor prognostic factors for MM</li> <li>• Overview the prognosis of relapsed / refractory disease</li> <li>• Outline treatment making decisions for refractory/relapsed (RR) multiple myeloma (MM)</li> <li>• Describe treatment options in the RR setting</li> <li>• Explain the role of stem cell transplant and CAR T trials in the treatment of RR MM</li> </ul>

## EXTENSION SEMINAR IN HAEMATOLOGY

## Program

All times listed are in AEDT

Saturday 15 October 2022

Time (AEDT)	Session
0850-0855	Online login available
0855-0900	<b>Welcome, introduction, housekeeping</b> Amanda Tey Senior Haematology Pharmacist, Monash Health, Melbourne, Vic Maggie Chau, Bone Marrow Transplant Pharmacist, The Royal Melbourne Hospital, Melbourne, Vic
0900-0940	<b>Review of self-paced learning package material and Q&amp;A</b> Amanda Tey & Maggie Chau
0940-0945	<b>Case session overview and introduction</b>
0945-1100	<b>Case session 1 (Case 1 - AML)</b> Led by Shevon Fernando, Senior Haematology Pharmacist, Alfred Health, Vic Tutor Team, Amanda Tey, Maggie Chau, Kyle Booth, Emily Harding, Philip Selby, Jackson Truong
1100-1115	<b>Case session 1 Recap and Q&amp;A</b>
1115-1130	<b>Break</b>
1130-1245	<b>Case session 2 (Case 2 - ALL)</b> Led by Maggie Chau Tutor Team, Amanda Tey, Kyle Booth, Shevon Fernando, Emily Harding, Philip Selby, Jackson Truong
1245-1300	<b>Case session 2 Recap and Q&amp;A</b>
1300-1330	<b>Lunch Break</b>
1330-1430	<b>Case session 3 (Case 3 – RR DLBCL)</b> Led by Amanda Tey Tutor Team, Maggie Chau, Kyle Booth, Shevon Fernando, Emily Harding, Philip Selby, Jackson Truong
1430-1440	<b>Case session 3 Recap and Q&amp;A</b>
1440-1540	<b>Case session 4 (Case 4 – RR MM)</b> Led by Amanda Tey Tutor Team, Maggie Chau, Kyle Booth, Shevon Fernando, Emily Harding, Philip Selby, Jackson Truong
1540-1550	<b>Case session 4 Recap and Q&amp;A</b>
1550-1600	<b>Break</b>
1600-1645	<b>Recap and Q&amp;A with competition quiz</b>
1645-1650	<b>Close of live virtual seminar</b>

*Please note: presentation recordings from the live virtual seminar will not be available.*